BioSpace News Archive

This morning, the Switzerland-based company said its SPIRIT-2 study met its co-primary efficacy endpoints and six key secondary endpoints for endometriosis treatment.

Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.

The goal is to support the discovery and development of next-generation drug and engineered cell therapies, specifically with a focus on natural killer (NK) cells.

A new life sciences facility dubbed The Labs has opened in Chicago providing necessary wet lab space for companies looking to expand their physical presence in the Windy City and cement the city’s reputation as a hub for cutting edge biomedical innovation.

Founded in 2012, New York City headquartered, Paragon Private Health (Paragon) helps create, implement and manage customized concierge medicine programs with private practice physicians to provide enhanced care for patients

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces the following statement regarding the impact of the COVID-19 pandemic on the company’s ongoing clinical development efforts: First, we would like to express our sincerest gratitude for all of the healthcare workers and other res

Salarius Pharmaceuticals, Inc., a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced that its chief executive officer, David Arthur, will deliver a virtual presentation at the Emerging Growth Invitational hosted by Diamond Equity Research and Veyo Partners on Tuesday, April 28, 2020.

CV Sciences, Inc., a preeminent supplier and manufacturer of hemp cannabidiol products, announced that it had filed a Shelf Registration Statement on Form S-3 with the Securities and Exchange Commission on April 21, 2020.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced it will report financial results for the first quarter of 2020 after market close on Monday, May 4, 2020.

Small molecule therapeutic inhibitors against coronaviruses included in agreement have demonstrated strong proof-of-concept and excellent efficacy data inMERS-CoV animal models